Stroke Prevention in Patients With Atrial Fibrillation: Focus on New Oral Anticoagulants

References

• . Kudenchuk PJ. Atrial fibrillation pearls and perils of management. West J Med. 1996;164(5):425–434
   PubMedGoogle Scholar
• . Miyasaka Y, Barnes ME, Gersh BJ, . Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119–125
   PubMed Web of Science ®Google Scholar
• . Centers for Disease Control and Prevention. Atrial fibrillation fact shee. http://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_atrial_fibrillation.htm. Updated December 20, 2010. Accessed
   Google Scholar
• . Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med. 1987;147(9):1561–1564
   PubMedGoogle Scholar
• . Singer DE, Albers GW, Dalen JE, ; American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133( 6 suppl):546S–592S
   Google Scholar
• . Birman-Deych E, Radford MJ, Nilasena DS, Gage BF. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke. 2006;37(4):1070–1074
   PubMed Web of Science ®Google Scholar
• . Gladstone DJ, Bui E, Fang J, . Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke. 2009;40(1):235–240
   PubMed Web of Science ®Google Scholar
• . Camm AJ, Lip GY, De Caterina R, ; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–2747
   PubMed Web of Science ®Google Scholar
• . Fuster V, Rydén LE, Cannom DS, Crijns HJ, ; Task Force on Practice Guidelines, American College of Cardiology/American Heart Association; Committee for Practice Guidelines, European Society of Cardiology; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J. 2006;27(16):1979–2030
   PubMedGoogle Scholar
• . Lip GY, Beevers DG, Singh SP, Watson RD. ABC of atrial fibrillation. Aetiology, pathophysiology, and clinical features. BMJ. 1995;311(7017):1425–1428
   PubMedGoogle Scholar
• . Al-Saady NM, Obel OA, Camm AJ. Left atrial appendage: structure, function, and role in thromboembolism. Heart. 1999;82(5):547–554
   PubMedGoogle Scholar
• . Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983–988
   PubMed Web of Science ®Google Scholar
• . Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154(13):1449–1457
   PubMedGoogle Scholar
• . Marini C, De Santis F, Sacco S, . Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005;36(6):1115–1159
   PubMed Web of Science ®Google Scholar
• . Dulli DA, Stanko H, Levine RL. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology. 2003;22(2):118–123
   PubMedGoogle Scholar
• . Tu HT, Campbell BC, Christensen S, ; Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) Investigators. Pathophysiological determinants of worse stroke outcome in atrial fibrillation. Cerebrovasc Dis. 2010;30(4):389–395
   PubMed Web of Science ®Google Scholar
• . Hart RG, Pearce LA Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867
   PubMed Web of Science ®Google Scholar
• . Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007;69(6):546–554
   PubMed Web of Science ®Google Scholar
• . Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–272
   PubMed Web of Science ®Google Scholar
• . Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500–1510
   PubMed Web of Science ®Google Scholar
• . Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864–2870
   PubMed Web of Science ®Google Scholar
• . van Walraven C, Hart RG, Singer DE, . Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA. 2002;288(19):2441–2448
   PubMed Web of Science ®Google Scholar
• . Fang MC, Go AS, Chang Y, Borowsky L, Pomernacki NK, Singer DE; ATRIA Study Group. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2008;51(8):810–815
   PubMed Web of Science ®Google Scholar
• . Samsa GP, Matchar DB, Goldstein LB, . Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med. 2000;160(7):967–973
   PubMed Web of Science ®Google Scholar
• . Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med. 2000;160(1):41–46
   PubMedGoogle Scholar
• . Härtter S, Sennewald R, Nehmiz G, Reilly P. Oral bioavailability of dabigatran etexilate (Pradaxa(®)) after co-medication with verapamil in healthy subjects [published online ahead of print September 5, 2012]. Br J Clin Pharmacol
   Google Scholar
• . Connolly SJ, Ezekowitz MD, Yusuf S, ; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151
   PubMed Web of Science ®Google Scholar
• . Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012;172(5):397–402
   PubMed Web of Science ®Google Scholar
• . Freeman JV, Zhu RP, Owens DK, . Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154(1):1–11
   PubMed Web of Science ®Google Scholar
• . Oldgren J, Alings M, Darius H, ; RE-LY Investigators. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med. 2011;155(10):660–667, W204
   PubMed Web of Science ®Google Scholar
• . Siegal DM, Crowther MA. Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J. 2013;34(7):489–498
   PubMed Web of Science ®Google Scholar
• . Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124(14):1573–1579
   PubMed Web of Science ®Google Scholar
• . Kreutz R. Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol. 2012;26(1):27–32
   PubMed Web of Science ®Google Scholar
• . Patel MR, Mahaffey KW, Garg J, ; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891
   PubMed Web of Science ®Google Scholar
• . Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med. 2011;49(5):761–772
   PubMed Web of Science ®Google Scholar
• . Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010;104(6):1263–1271
   PubMed Web of Science ®Google Scholar
• . Raghavan N, Frost CE, Yu Z, . Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37(1):74–81
   PubMed Web of Science ®Google Scholar
• . Eliquis [package insert]. Middlesex, UK: Bristol-Myers Squibb/Pfizer EEIG; 2011. http://www.pfizer.ca/en/our_products/products/mono-graph/313. Accessed March 2, 2013
   Google Scholar
• . Connolly SJ, Eikelboom J, Joyner C, ; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–817
   PubMed Web of Science ®Google Scholar
• . Granger CB, Alexander JH, McMurray JJ, ; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992
   PubMed Web of Science ®Google Scholar
• . Lopes RD, Alexander JH, Al-Khatib SM, ; ARISTOTLE Investigators. Apixaban for reduction in stroke and other Thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010;159(3):331–339
   PubMed Web of Science ®Google Scholar
• . Mega JL. A new era for anticoagulation in atrial fibrillation. N Engl J Med. 2011;365(11):1052–1054
   PubMedGoogle Scholar
• . Adam SS, McDuffie JR, Ortel TL, Williams Jr JW. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med. 2012;157(11):796–807
   PubMed Web of Science ®Google Scholar
• . Harenberg J, Wehling M. Future of anticoagulant therapy. Cardiovasc Ther. 2011;29(5):291–300
   PubMedGoogle Scholar